43 0 2

Partnering

MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

Company Highlights

  • Robust pipeline in oncology, autoimmunity and infectious diseases
  • Partners include Boehringer Ingelheim, Pfizer and Servier
  • Fully-integrated biologics capabilities across product development process 
  • Strong financial position and blue-chip investor base
  • Experienced management team and highly collaborative corporate culture 
Learn more

Overview

Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.

Learn more

In the News

2009 News Archive

August 13, 2009 | Science Business Exchange
Dousing Diabetes' Flames

August 06, 2009 | JDRF Countdown to a Cure
The Progression of Anti-CD3 Trials

July 27, 2009 | Washington Business Journal
D.C. Area Contains Job-Seeking Startups

July 24, 2009 | Gazette
Biotech Industry In Battle Over Data

July 03, 2009 | Washington Business Journal
Biotech: The Next Generation

June 30, 2009 | USA Today
Experiment Seeks To Head Off Type 1 Diabetes

June 26, 2009 | Washington Business Journal
Local Biotechs Search For Partners To Help Them Survive

March 23, 2009 | The Washington Post
No Money, No Buyers For Struggling Biotech Firms

News Archive: 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | View All